Showing results (1341-1350 of 1,717) with videos related to

Sort By:
Pageof 172
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Annals of Surgical Oncology|November 21, 2024
Surgical Site Infections in Simultaneous Colorectal and Liver Resections for Metastatic Colorectal AdenocarcinomaLauren E Schleimer, Lynn Hakki, Kenneth Seier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE StudyDavid A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|August 26, 2020
[Population's acceptance and attitude toward a novel fecal immunochemical test for colorectal cancer screening: a multi-center survey in China]H Wang, C C Liu, F Z Bai, et al.
Blood|June 19, 2013
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionDaniel Thomas, Jason A Powell, Francois Vergez, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Cancer Cell|September 30, 2022
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responsesKah Lok Chan, Juliana Gomez, Chelisa Cardinez, et al.
Blood|January 15, 2020
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AMLC D DiNardo, I S Tiong, A Quaglieri, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Pageof 172